CompletedPhase 2

Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis

Taiwan27 participantsStarted 2007-11

Plain-language summary

To evaluate the efficacy of SR-T100 gel by observing the lesion size (length x width x height) of human cutaneous squamous cell carcinoma in situ (Actinic Keratosis and Bowen's Disease) reduced at least 75%.

Who can participate

Age range

20 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Male or female; aged ≧ 20 years old.
. Patients had histologically confirmed Squamous cell carcinoma in situ (AK or BD) for the targeted lesion.
. Patients had a measurable lesion 5mm or larger for AK or 10mm or larger for BD.
. Patient had a performance status of \< 2 (ECOG).
. Patients who had signed an approved written informed consent.

Exclusion criteria

. Patients with histologic subtypes other than squamous cell carcinoma in situ (AK or BD).
. Patients with tumor extending into the oral cavity, nostrils, eyelids, urethra, anus, vagina or rectum.
. Patients who had grossly suspicious or inflamed nodes on physical examination.
. Patients with grossly infected tumors.
. Patients with recurrent invasive squamous cell carcinoma.
. Patients with a history of other invasive malignancies, if there was any evidence of the other malignancy being present within the past 5 years. Patients were also excluded if their previous cancer treatment contraindicated this protocol therapy.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Partial clearance rate

Timeframe: 16 weeks treatment and 4 weeks follow-up

Trial details

NCT IDNCT02085395

SponsorG&E Herbal Biotechnology Co., LTD

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-04

View on ClinicalTrials.gov More Actinic Keratosis trials